GeneDx Smashes Earnings, Pushes Genomic Advancements

GeneDx delivers impressive Q1 2025 earnings, surpassing expectations with $87.1M revenue and $7.7M adjusted net income. They raise full-year guidance to $360-$375M, driven by robust growth in exome and genome testing. Despite weather challenges, volumes for flagship tests increased 24%, setting a strong pace for Q2. GeneDx is revolutionizing genetic disease diagnosis, offering proactive whole exome and genome sequencing, reducing unnecessary tests and misdiagnoses. Theyre expanding into ultra-rapid genome sequencing for NICUs and AI interpretation with Fabric Genomics acquisition, positioning themselves as leaders in genomic newborn screening and biopharma data plays. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/69047bf6bcfc0184